StocktoriaCyclerion Therapeutics, Inc. CYCN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $2.1M | $2.0M | $0 | $297,000 | $3.9M |
| Operating income | -$5.0M | -$3.6M | -$13.0M | -$18.5M | -$55.2M |
| Net income | -$3.5M | -$3.1M | -$5.3M | -$44.1M | -$51.6M |
| Operating cash flow | -$3.3M | -$4.3M | -$21.2M | -$40.6M | -$36.5M |
| Free cash flow | — | — | — | -$40.6M | -$36.5M |
| Total assets | $10.0M | $9.6M | $13.4M | $18.1M | $59.3M |
| Shareholders' equity | $9.1M | $8.8M | $11.3M | $10.5M | $48.2M |
| Ratios | |||||
| Operating margin | -239.8% | -181.4% | — | -6242.4% | -1400.2% |
| Net margin | -170.1% | -152.8% | — | -14841.1% | -1310.2% |
| FCF margin | — | — | — | -13673.7% | -926.5% |
| Return on assets | -35.3% | -31.9% | -39.4% | -243.8% | -87.0% |
| Return on equity | -38.8% | -34.5% | -46.6% | -421.7% | -107.0% |
| Current ratio | 5.15 | 5.83 | 3.85 | 1.94 | 5.00 |
| Revenue growth | 3.7% | — | -100.0% | -92.5% | 71.7% |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001755237 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.